Change of health-related profiles after Imatinib cessation in chronic phase chronic myeloid leukemia patients

Joon Seong Park; Sung Eun Lee; Seong Hyun Jeong; Eun Jung Jang; Mi Yeon Choi; Hyeoung Joon Kim; Yeo Kyeoung Kim; Sung Hyun Kim; Dae Young Zang; Sukjoong Oh; Dong Hoe Koo; Hawk Kim; Young Rok Do; Jae Yong Kwak; Jeong A. Kim; Dae Young Kim; Yeung Chul Mun; Won Sik Lee; Myung Hee Chang; Jinny Park; Ji Hyun Kwon; Dong Wook Kim

doi:10.3109/10428194.2015.1049166

Change of health-related profiles after Imatinib cessation in chronic phase chronic myeloid leukemia patients

Joon Seong Park, Sung Eun Lee, Seong Hyun Jeong, Eun Jung Jang, Mi Yeon Choi, Hyeoung Joon Kim, Yeo Kyeoung Kim, Sung Hyun Kim, Dae Young Zang, Sukjoong Oh, Dong Hoe Koo, Hawk Kim, Young Rok Do, Jae Yong Kwak, Jeong A. Kim, Dae Young Kim, Yeung Chul Mun, Won Sik Lee, Myung Hee Chang, Jinny ParkJi Hyun Kwon, Dong Wook Kim

Department of Internal Medicine

Research output: Contribution to journal › Article › peer-review

24 Scopus citations

Abstract

The aim of this study was to investigate the changes in health-related profiles including quality-of-life (HRQoL) in the chronic myeloid leukemia (CML) patients who discontinued imatinib (IM). An HRQoL survey composed of 43 parameters about IM-related adverse events (AEs), physical health-related and mental health-related was provided at baseline and 6 months post-discontinuation. A total of 55 patients with a sustained UMRD over 6 months were analyzed. Although the majority of IM-related AEs were significantly improved, unexpectedly pruritus and musculoskeletal pain worsen or newly develop in 29.1% and 21.8% of patients, respectively. The improvements in physical and mental health condition were variable in individual patients. In addition, rapid restorations of the hematological and biochemical parameters were observed. The results showed the changes of HRQoL and laboratory tests in treatment-off patients and the necessity of continuing physical and mental support for some patients in tyrosine kinase inhibitor (TKI)-off studies.

Original language	English
Pages (from-to)	341-347
Number of pages	7
Journal	Leukemia and Lymphoma
Volume	57
Issue number	2
DOIs	https://doi.org/10.3109/10428194.2015.1049166
State	Published - 1 Feb 2016

Bibliographical note

Publisher Copyright:
© 2015 Informa UK, Ltd.

Keywords

Chronic myeloid leukemia
imatinib cessation
quality-of-life

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3109/10428194.2015.1049166

Cite this

Park, J. S., Lee, S. E., Jeong, S. H., Jang, E. J., Choi, M. Y., Kim, H. J., Kim, Y. K., Kim, S. H., Zang, D. Y., Oh, S., Koo, D. H., Kim, H., Do, Y. R., Kwak, J. Y., Kim, J. A., Kim, D. Y., Mun, Y. C., Lee, W. S., Chang, M. H., ... Kim, D. W. (2016). Change of health-related profiles after Imatinib cessation in chronic phase chronic myeloid leukemia patients. Leukemia and Lymphoma, 57(2), 341-347. https://doi.org/10.3109/10428194.2015.1049166

@article{4ecf8ed9e4534e68b45c61028fefcf3a,

title = "Change of health-related profiles after Imatinib cessation in chronic phase chronic myeloid leukemia patients",

abstract = "The aim of this study was to investigate the changes in health-related profiles including quality-of-life (HRQoL) in the chronic myeloid leukemia (CML) patients who discontinued imatinib (IM). An HRQoL survey composed of 43 parameters about IM-related adverse events (AEs), physical health-related and mental health-related was provided at baseline and 6 months post-discontinuation. A total of 55 patients with a sustained UMRD over 6 months were analyzed. Although the majority of IM-related AEs were significantly improved, unexpectedly pruritus and musculoskeletal pain worsen or newly develop in 29.1% and 21.8% of patients, respectively. The improvements in physical and mental health condition were variable in individual patients. In addition, rapid restorations of the hematological and biochemical parameters were observed. The results showed the changes of HRQoL and laboratory tests in treatment-off patients and the necessity of continuing physical and mental support for some patients in tyrosine kinase inhibitor (TKI)-off studies.",

keywords = "Chronic myeloid leukemia, imatinib cessation, quality-of-life",

author = "Park, {Joon Seong} and Lee, {Sung Eun} and Jeong, {Seong Hyun} and Jang, {Eun Jung} and Choi, {Mi Yeon} and Kim, {Hyeoung Joon} and Kim, {Yeo Kyeoung} and Kim, {Sung Hyun} and Zang, {Dae Young} and Sukjoong Oh and Koo, {Dong Hoe} and Hawk Kim and Do, {Young Rok} and Kwak, {Jae Yong} and Kim, {Jeong A.} and Kim, {Dae Young} and Mun, {Yeung Chul} and Lee, {Won Sik} and Chang, {Myung Hee} and Jinny Park and Kwon, {Ji Hyun} and Kim, {Dong Wook}",

note = "Publisher Copyright: {\textcopyright} 2015 Informa UK, Ltd.",

year = "2016",

month = feb,

day = "1",

doi = "10.3109/10428194.2015.1049166",

language = "English",

volume = "57",

pages = "341--347",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "2",

}

Park, JS, Lee, SE, Jeong, SH, Jang, EJ, Choi, MY, Kim, HJ, Kim, YK, Kim, SH, Zang, DY, Oh, S, Koo, DH, Kim, H, Do, YR, Kwak, JY, Kim, JA, Kim, DY, Mun, YC, Lee, WS, Chang, MH, Park, J, Kwon, JH & Kim, DW 2016, 'Change of health-related profiles after Imatinib cessation in chronic phase chronic myeloid leukemia patients', Leukemia and Lymphoma, vol. 57, no. 2, pp. 341-347. https://doi.org/10.3109/10428194.2015.1049166

TY - JOUR

T1 - Change of health-related profiles after Imatinib cessation in chronic phase chronic myeloid leukemia patients

AU - Park, Joon Seong

AU - Lee, Sung Eun

AU - Jeong, Seong Hyun

AU - Jang, Eun Jung

AU - Choi, Mi Yeon

AU - Kim, Hyeoung Joon

AU - Kim, Yeo Kyeoung

AU - Kim, Sung Hyun

AU - Zang, Dae Young

AU - Oh, Sukjoong

AU - Koo, Dong Hoe

AU - Kim, Hawk

AU - Do, Young Rok

AU - Kwak, Jae Yong

AU - Kim, Jeong A.

AU - Kim, Dae Young

AU - Mun, Yeung Chul

AU - Lee, Won Sik

AU - Chang, Myung Hee

AU - Park, Jinny

AU - Kwon, Ji Hyun

AU - Kim, Dong Wook

PY - 2016/2/1

Y1 - 2016/2/1

N2 - The aim of this study was to investigate the changes in health-related profiles including quality-of-life (HRQoL) in the chronic myeloid leukemia (CML) patients who discontinued imatinib (IM). An HRQoL survey composed of 43 parameters about IM-related adverse events (AEs), physical health-related and mental health-related was provided at baseline and 6 months post-discontinuation. A total of 55 patients with a sustained UMRD over 6 months were analyzed. Although the majority of IM-related AEs were significantly improved, unexpectedly pruritus and musculoskeletal pain worsen or newly develop in 29.1% and 21.8% of patients, respectively. The improvements in physical and mental health condition were variable in individual patients. In addition, rapid restorations of the hematological and biochemical parameters were observed. The results showed the changes of HRQoL and laboratory tests in treatment-off patients and the necessity of continuing physical and mental support for some patients in tyrosine kinase inhibitor (TKI)-off studies.

AB - The aim of this study was to investigate the changes in health-related profiles including quality-of-life (HRQoL) in the chronic myeloid leukemia (CML) patients who discontinued imatinib (IM). An HRQoL survey composed of 43 parameters about IM-related adverse events (AEs), physical health-related and mental health-related was provided at baseline and 6 months post-discontinuation. A total of 55 patients with a sustained UMRD over 6 months were analyzed. Although the majority of IM-related AEs were significantly improved, unexpectedly pruritus and musculoskeletal pain worsen or newly develop in 29.1% and 21.8% of patients, respectively. The improvements in physical and mental health condition were variable in individual patients. In addition, rapid restorations of the hematological and biochemical parameters were observed. The results showed the changes of HRQoL and laboratory tests in treatment-off patients and the necessity of continuing physical and mental support for some patients in tyrosine kinase inhibitor (TKI)-off studies.

KW - Chronic myeloid leukemia

KW - imatinib cessation

KW - quality-of-life

UR - http://www.scopus.com/inward/record.url?scp=84954466698&partnerID=8YFLogxK

U2 - 10.3109/10428194.2015.1049166

DO - 10.3109/10428194.2015.1049166

M3 - Article

AN - SCOPUS:84954466698

SN - 1042-8194

VL - 57

SP - 341

EP - 347

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 2

ER -

Change of health-related profiles after Imatinib cessation in chronic phase chronic myeloid leukemia patients

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this